VBI Vaccines (NASDAQ: VBIV) is a commercial-stage biopharmaceutical company that develops vaccine candidates and novel technology platforms in Israel and internationally. The company’s products are based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allow vaccines and biologics to preserve stability, potency, and safety. The company’s commercial stage product is Sci-B-Vac, a third-generation licensed hepatitis B vaccine for adults, children, and newborn infants. It is also involved in CMV vaccine program, which is in phase I clinical trials for the prevention of cytomegalovirus infection; GBM immunotherapy program, a preclinical stage glioblastoma multiforme therapeutic vaccine candidate; and RSV vaccine program, a discovery stage novel respiratory syncytial virus vaccine candidate. For more information, visit the company’s website www.vbivaccines.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
